Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals Balance Sheet Statement

Assets, liabilities, and shareholders' equity

Alnylam Pharmaceuticals holds $5.1B in total assets. Shareholders' equity is $1.1B against $263.7M in total debt. Cash and equivalents total $1.7B. The current ratio is 3.13 and debt-to-equity is 0.245. Based on the Q1 2026 filing.

Total Assets$5.1BTotal Stockholders Equity$1.1BLong Term Debt-Cash And Equivalents$1.7BTotal Current Assets$4.2BTotal Current Liabilities$1.3B
Latest FilingQ1 2026
Report Date2026-04-30
Market Cap$38.6B
P/E Ratio76.91
ROE66.91%

Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts receivable, net$405.3M$418M$567.1M$964.8M$777.6M$884M
Cash and cash equivalents$968.7M$1B$1.1B$1.5B$1.7B$1.7B
Available For Sale Securities Debt Securities Current$1.7B$1.6B$1.7B$1.2B$1.3B$1.3B
Finished goods$26.4M$33M$33.7M$38.9M$32.3M$39M
Raw materials$24M$23.4M$22.9M$22.3M$14.2M$11.7M
Work in process$65M$54M$43.8M$35.5M$65.1M$65.5M
Inventories$78.5M$65.6M$71.7M$75.4M$82.7M$84M
Prepaid expenses and other current assets$117M$152.4M$147.3M$188M$281.9M$242.1M
Restricted cash—$2.6M$2.2M$2.6M—$1.6M
Short-term investments$1.7B$1.6B$1.7B$1.2B$1.3B$1.3B
Total current assets$3.3B$3.3B$3.6B$4B$4.1B$4.2B

Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accrued Contingent Liabilities$0———$0—
Accrued expenses$793.7M$704.2M$919M$1.2B$1.1B$946.5M
Other Commercial Liabilities$793.7M$704.2M$919M$1.2B$1.1B$946.5M
Accrued Liabilities, Current$793.7M$704.2M$919M$1.2B$1.1B$946.5M
Liabilities related to the sale of future royalties and development funding$113M———$220.1M$227.5M
Deferred revenue$55.5M$28.2M$15.1M$2.5M$4.8M$3.2M
Operating lease liabilities, current$41.9M$46M$46.1M$44.8M$45.5M$45.7M
Total current liabilities$1.2B$1.1B$1.3B$1.6B$1.5B$1.3B

Equity

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Additional paid-in capital$7.4B$7.5B$7.7B$7.4B$7.5B$7.6B
Accumulated other comprehensive income (loss)-$34.5M-$37.5M-$30M-$21.8M-$20.1M-$24.9M
Common stock1.3M250M250M250M250M250M
Common Stock Par Value Per Share$0.01$0.01$0.01$0.01$0.01$0.01
Common Stock Shares Issued129.3M130.3M131M131.8M132.4M133.4M
Convertible Preferred Stock Authorized Shares5M5M5M5M5M5M
Convertible Preferred Stock Issued Shares000000
Convertible Preferred Stock Outstanding Shares000000
Additional paid-in capital$7.4B$7.5B$7.7B$7.4B$7.5B$7.6B
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively$1.3M$1.3M$1.3M$1.3M$1.3M$1.3M
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding$0$0$0$0$0$0
Preferred stock$0$0$0$0$0$0
Preferred Stock Par Value Per Share$0.01$0.01$0.01$0.01$0.01$0.01
Retained earnings-$7.3B-$7.3B-$7.4B-$7.2B-$6.7B-$6.5B
Total liabilities and stockholders' equity$4.2B$4.2B$4.6B$4.9B$5B$5.1B
Total stockholders' equity$67.1M$426.1M$250.6M$233.9M$789.2M$1.1B

Non-Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Convertible Debt (Non-Current)$1B$1B$1B$1B$1B$1B
Operating lease liabilities, non-current$229.5M$230.1M$224.4M$223.4M$225.1M$218M
Other non-current liabilities$5M$5.9M$10.9M$9.8M$7.6M$7.6M
Total liabilities$4.2B$4.1B$4.3B$4.6B$4.2B$4.1B

Non-Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Deferred Tax Assets and Other Non-Current Assets$65.3M$73.8M$57.2M$55.8M$59.5M$63.6M
Net Investment in Lease$191.1M$197.2M$192.4M$191.4M$194.9M$189.3M
Deferred tax assets$116.9M$107.2M$104.4M$98.6M$126M$117M
Operating lease right-of-use assets$191.1M$197.2M$192.4M$191.4M$194.9M$189.3M
Other non-current assets$65.3M$73.8M$57.2M$55.8M$59.5M$63.6M
Operating lease right-of-use assets$191.1M$197.2M$192.4M$191.4M$194.9M$189.3M
Operating Lease Right-of-Use Assets in Other Assets$191.1M$197.2M$192.4M$191.4M$194.9M$189.3M
Other non-current assets$65.3M$73.8M$57.2M$55.8M$59.5M$63.6M
Property and equipment, net$502.8M$498.7M$499.8M$501.8M$513.1M$518.3M
Software and Technology Licenses, Net$65.3M$73.8M$57.2M$55.8M$59.5M$63.6M
Total assets$4.2B$4.2B$4.6B$4.9B$5B$5.1B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Common stock, par value (in dollars per share)$0$0$0$0$0$0
Common stock, shares authorized (in shares)$250M$250M$250M$250M$250M$250M
Common stock, shares issued (in shares)$129.3M$130.3M$131M$131.8M$132.4M$133.4M
Common Stock, Shares, Outstanding$129.3M$130.3M$131M$131.8M$132.4M$133.4M
Convertible debentures$1B$1B$1B$1B$1B$1B
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax, Including Cash Equivalents————$88K$1.4M
Gross Unrealized Gains————$3.4M$1.1M
Debt Securities, Available-for-Sale, Amortized Cost, Including Cash Equivalents————$1.3B$1.6B
Fair Value————$1.3B$1.6B
Inventory, Current And Noncurrent$115.4M$110.3M$100.4M$96.6M$111.6M$116.1M
Raw materials$24M$23.4M$22.9M$22.3M$14.2M$11.7M
Loss Contingency Accrual$0———$0—
Number of commercialized products—4.004.004.00—4.00
Number of partnered products—2.002.002.00—2.00
Number of marketed products—6.006.006.00—6.00
Preferred Stock, Par or Stated Value Per Share$0$0$0$0$0$0
Preferred Stock, Shares Authorized$5M$5M$5M$5M$5M$5M
Preferred Stock, Shares Issued$0$0$0$0$0$0
Preferred Stock, Shares Outstanding$0$0$0$0$0$0
Restricted Investments, Noncurrent$68.6M$68.6M$68.6M$51.3M$22.2M$22.2M
Liabilities related to the sale of future royalties and development funding, net of current portion$1.3B———$1.5B$1.5B
Valuation Allowances And Reserves Balance$361.8M—$473.9M$559.4M$425.7M$477M